You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
|
|---|---|
| Published in |
Molecular Cancer, March 2010
|
| DOI | 10.1186/1476-4598-9-57 |
| Pubmed ID | |
| Authors |
Didier Roulin, Yannick Cerantola, Anne Dormond-Meuwly, Nicolas Demartines, Olivier Dormond |
| Abstract |
The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions of mTORC2 in cancer progression. In this study, we explored the specific role of mTORC2 in colon cancer using a short hairpin RNA expression system to silence the mTORC2-associated protein rictor. We found that downregulation of rictor in HT29 and LS174T colon cancer cells significantly reduced cell proliferation. Knockdown of rictor also resulted in a G1 arrest as observed by cell cycle analysis. We further observed that LS174T cells deficient for rictor failed to form tumors in a nude mice xenograft model. Taken together, these results show that the inhibition of mTORC2 reduces colon cancer cell proliferation in vitro and tumor xenograft formation in vivo. They also suggest that specifically targeting mTORC2 may provide a novel treatment strategy for colorectal cancer. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | 2% |
| Mexico | 1 | 2% |
| Netherlands | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 50 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 20% |
| Student > Ph. D. Student | 11 | 20% |
| Student > Bachelor | 8 | 15% |
| Student > Master | 7 | 13% |
| Student > Doctoral Student | 6 | 11% |
| Other | 6 | 11% |
| Unknown | 5 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 24 | 44% |
| Biochemistry, Genetics and Molecular Biology | 14 | 26% |
| Medicine and Dentistry | 8 | 15% |
| Chemistry | 3 | 6% |
| Unknown | 5 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2011.
All research outputs
#20,184,694
of 22,699,621 outputs
Outputs from Molecular Cancer
#1,474
of 1,715 outputs
Outputs of similar age
#89,506
of 93,788 outputs
Outputs of similar age from Molecular Cancer
#21
of 21 outputs
Altmetric has tracked 22,699,621 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,715 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 93,788 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.